HB1275 would repeal existing Missouri statutes related to gender transition procedures and replace them with new provisions that restrict certain gender-affirming medical treatments. The bill creates a new section, the “Missouri Save Adolescents from Experimentation (SAFE) Act,” defining terms such as biological sex, gender transition, gender transition surgery, cross-sex hormones, and puberty-blocking drugs. Under the bill, healthcare providers would be prohibited from knowingly performing gender transition surgery on anyone under 18 and from prescribing or administering cross-sex hormones or puberty-blocking drugs to minors for the purpose of gender transition, with a limited grandfather clause for minors already receiving such treatment before August 28, 2023, and a sunset date of August 28, 2027 for the hormone/puberty-blocker restriction.
The bill also adds enforcement mechanisms. A violation would be treated as unprofessional conduct subject to license revocation, and it would create a private right of action against providers, with expanded damages, attorney’s fees, and special evidentiary rules. The bill includes exceptions for certain disorders of sex development, treatment of complications or injuries, and emergency procedures necessary to prevent death or major bodily impairment. It also states that the section does not apply to speech protected by the First Amendment.
In addition to the new SAFE Act section, HB1275 amends Missouri health and correctional-care statutes to exclude gender transition surgery from covered services. It removes references to gender transition surgery from MO HealthNet, correctional center healthcare, and county jail medical care provisions, meaning state Medicaid and correctional systems would not pay for or provide such surgeries. The bill also preserves a broad set of existing MO HealthNet benefits, but specifically bars payments for gender transition surgeries, cross-sex hormones, and puberty-blocking drugs for the purpose of gender transition.
The general sentiment reflected by the bill text is strongly restrictive and oppositional toward gender-affirming care for minors, while still preserving narrow medical exceptions. Because there are no committee transcripts or recorded votes in the provided material, there is no documented floor or committee debate to gauge broader legislative sentiment beyond the bill’s sponsor-driven framing and its explicit policy choices. The bill’s structure suggests the main policy goal is to prohibit and deter gender transition-related treatment for minors through both licensing penalties and civil liability.
The main points of contention likely center on the scope of the ban, the private lawsuit provision, and the medical exceptions. Supporters would likely view the bill as protecting minors and limiting irreversible treatment, while opponents would likely argue it interferes with physician judgment, targets transgender youth, and creates legal risk for healthcare providers. The inclusion of a grandfather clause, a sunset date for hormone and puberty-blocker restrictions, and exceptions for disorders of sex development indicate attempts to narrow the bill, but the overall effect remains a significant restriction on gender-affirming care and related public coverage.
HB1275 would repeal and replace Missouri statutes governing gender transition procedures, directly affecting MO HealthNet coverage rules, correctional healthcare obligations, and county jail medical-care provisions. It would prohibit state payment for gender transition surgeries, cross-sex hormones, and puberty-blocking drugs for the purpose of gender transition, and it would remove gender transition surgery from the list of services that correctional facilities and jails may provide or fund. It also creates new licensing and civil-liability consequences for healthcare providers, which would alter professional practice standards and expose providers to revocation and damages claims.
The bill’s overall sentiment is restrictive and adversarial toward gender-affirming medical care for minors. The text reflects a clear policy preference to prohibit such treatments, limit public funding, and impose enforcement mechanisms against providers. No committee testimony or vote record was provided, so there is no additional evidence of bipartisan support or organized opposition from the legislative process in the supplied materials.
The most notable points of contention are likely the ban on gender transition surgery, cross-sex hormones, and puberty-blocking drugs for minors; the creation of a private right of action with enhanced damages and attorney’s fees; and the impact on physician discretion and patient access to care. Opponents would likely object to the bill’s restrictions on gender-affirming treatment and its legal penalties for providers, while supporters would likely argue the bill protects minors from irreversible interventions. The bill’s exceptions for disorders of sex development and emergency medical treatment appear designed to address anticipated criticism, but they do not eliminate the core controversy over restricting care for transgender youth.